Observational studies and randomized clinical trials demonstrating that antiretroviral prophylaxis of the breastfeeding infant or triple-drug antiretroviral prophylaxis of the lactating mother can significantly affect the risk of postnatal transmission of HIV via breast milk have recently become available. In resource-limited countries, breastfeeding is a cornerstone of infant survival. While shortening the duration of breastfeeding by HIV-infected women reduces postnatal HIV transmission, increasing data suggest this may also decrease overall infant survival. Thus, there is a crucial need for interventions to allow safer and more prolonged breastfeeding. This paper will critically review the results of studies of postnatal antiretroviral prophylaxis to prevent breast milk HIV transmission.
In 2008, an estimated 430,000 children were infected with HIV worldwide [1] . The vast majority of these infections were acquired by mother-to-child HIV transmission occurring in utero, intrapartum or through breastfeeding. Over 90% of these new paediatric infections occurred in sub-Saharan Africa, where acquisition of HIV through breast milk accounts for an estimated 40% or more of new infections, but where breastfeeding has long been a cornerstone of child survival programmes. HIV-infected mothers in this setting are faced with an agonizing choice: to breastfeed but risk transmitting HIV to their infant or to not breastfeed and risk their infant dying of malnutrition or other infectious diseases. Exclusive breastfeeding can lower the risk of postnatal HIV transmission compared to mixed feeding, but it does not eliminate risk [2, 3] .
In well-resourced countries, such as the United States, early identification of HIV infection in pregnant women through universal routine opt-out antenatal HIV testing, provision of antiretroviral therapy for HIV-infected women who need treatment for their own health, provision of antiretroviral prophylaxis if therapy is not yet required, elective caesarean delivery and complete avoidance of breastfeeding has dramatically reduced the risk of mother-to-child HIV transmission to approximately 1-2% [4] .
More than a decade ago, clinical trials identified simple, effective and relatively inexpensive antiretroviral interventions to prevent mother-to-child transmission during pregnancy and delivery that are applicable to resource-limited settings; however, implementation of these interventions has been slow. The proportion of pregnant women accessing antenatal HIV testing in midand low-resource countries has increased from 10% to 21% between 2007 and 2009, and the proportion of HIV-infected pregnant women receiving antiretroviral drugs for prevention of transmission has increased from 11% to 45% during the same period; however, almost one-quarter of pregnant women globally do not access any antenatal care and many countries continue to use less effective antiretroviral interventions, such as singledose nevirapine alone, for prevention of transmission [5, 6] . Importantly, although the current antepartum and peripartum antiretroviral prophylaxis regimens reduce the risk of in utero and intrapartum transmission, the subsequent risk of HIV transmission through breastfeeding remains high and can result in postnatal transmission rates >15% with prolonged breastfeeding [3] .
The only method that can eliminate breastfeedingassociated HIV transmission is to completely avoid breastfeeding. This is recommended in settings in which replacement feeding is affordable and sustainable, clean water is widely available, hygiene and sanitary conditions are good, and deaths caused by infectious diarrhoeal and respiratory diseases are relatively uncommon. This approach, however, is not feasible or safe in many Introduction resource-limited countries, where there are high rates of infant morbidity, mortality and malnutrition, and the high costs of formula, inadequate replacement foods to meet the nutritional needs of a growing infant, unsafe water supply, and stigma associated with not breastfeeding make replacement feeding untenable.
In the past year, exciting new results from randomized clinical trials have become available demonstrating that antiretroviral prophylaxis of the breastfeeding infant or the lactating mother can significantly decrease the risk of postnatal acquisition of HIV. Available data suggest that implementation of these postpartum antiretroviral interventions, combined with treatment of HIV-infected pregnant and lactating women who require treatment for their own health and antepartum and intrapartum antiretroviral prophylaxis interventions for those not requiring treatment, could decrease mother-to-child transmission rates in resource-limited countries to <4%.
The crucial need to provide antiretroviral therapy to pregnant and lactating women
Clinical trials of interventions to prevent mother-to-child transmission have largely focused on use of antiretroviral drugs solely for prevention of transmission, without consideration of what might be optimal treatment for the mother. Given the inextricable link between maternal and infant survival, this approach is short-sighted, and only interventions that address maternal health as well as prevention of transmission are likely to provide maximal benefit.
Although this paper is focused on antiretroviral prophylaxis to prevent postnatal HIV transmission, prevention of mother-to-child transmission should begin during pregnancy and must consider maternal health status. A key issue related to choosing an antiretroviral regimen for an HIV-infected pregnant woman (or for a postpartum lactating woman) is whether the antiretroviral drugs are being provided for treatment (in which case combination antiretroviral therapy should be provided and continued for life) or solely for prophylaxis of mother-tochild transmission (in which case less intensive regimens might be equally as effective as combination antiretroviral therapy, and the antiretroviral drug therapy would be stopped when the risk of transmission has ceased).
The 2006 WHO guidelines on when to treat pregnant women recommended treating all women with WHO clinical stage 4; for women with WHO clinical stage 3, starting when CD4 + T-cell count is <350 cells/µl; but for women with WHO clinical stage 1 or 2, which constitute the vast majority of pregnant women, therapy was only recommended if CD4 + T-cell count was <200 cells/ µl [7] . In 2009, WHO updated these guidelines to recommend treatment for all HIV-infected adults, pregnant and non-pregnant, with CD4 + T-cell count <350 T-cell count [8, 9] , based on results from a clinical trial from Haiti that demonstrated improved survival and decreased morbidity in non-pregnant adults initiating treatment at a CD4 + T-cell threshold of <350 cells/µl compared with <200 cells/µl [10] .
In pregnant and lactating women, both maternal mortality as well as risk of mother-to-child transmission is associated with CD4 + T-cell count, and use of a higher CD4 + T-cell threshold to determine when to initiate lifelong therapy is particularly important as it affects outcome for both mother and child. Looking specifically at postnatal transmission risk, in the absence of antiretroviral prophylaxis, 12-18-month postnatal infection rates in infants uninfected at 4-6 weeks of age born to mothers with baseline CD4 + T-cell count <350 cells/µl were as high as 17%, whereas infants of mothers with CD4 + T-cell count >350 cells/µl had postnatal infection rates of 2-6% ( [16] . In a study in Kenya, overall maternal mortality at 1 and 2 years postpartum was 2% and 6%, respectively; all deaths occurred in women with CD4 + T-cell count <350 cells/µl at 32 weeks gestation (20/169; 12% died by 2 years postpartum), with no deaths in women with CD4 + T-cell count >350 cell/µl [17] . Because the majority of HIV-infected pregnant women are asymptomatic or have only mild symptoms (unlike adults enrolled in HIV care and treatment programmes who are often symptomatic) [18] , it is critical that programmes that provide care to pregnant (and lactating) women provide access to CD4 + T-cell lymphocyte assays to determine which women need to initiate antiretroviral treatment for their own health benefit that would be continued for life. Interventions provided solely for prophylaxis of transmission, which stop after transmission risk has ceased (upon complete cessation of breastfeeding), should therefore theoretically be restricted to women without clinical symptoms and with CD4 + T-cell count >350 cells/µl. In studies from Kenya and Côte d'Ivorie, approximately 52-65% of HIV-infected pregnant women seen in antenatal clinics had CD4 + T-cell count >350 cells/µl [17, 19] .
Prevention of postnatal transmission through breastfeeding using antiretroviral drugs
Two types of antiretroviral interventions to prevent postnatal transmission have been evaluated in observational studies and clinical trials in resource-limited settings: provision of antiretroviral drugs to infants exposed to HIV during breastfeeding [20] [21] [22] [23] [24] [25] and provision of combination antiretroviral prophylaxis to lactating women [25] [26] [27] [28] [29] [30] [31] [32] . The design of these studies is shown in Table 2 . Detailed comparative information for the infant prophylaxis studies is shown in Table 3 , and for the maternal prophylaxis studies is shown in Table 4 . Both of these strategies have been predicated on breastfeeding during the period of most benefit, followed by early weaning (for example, at or before age 6 months). Although the benefit of breastfeeding in terms of reducing infant mortality appears to be greatest in the first 6 months of life in resource-limited countries, significant benefit is furthermore observed throughout the first year of life [33] . Cessation of breastfeeding at age 6 months might be associated with increased morbidity and mortality in infants, as will be discussed later.
There are major differences between studies, particularly between maternal and infant prophylaxis studies, which make it difficult to compare absolute HIV transmission rates between the studies. Reports often lack a 95% confidence interval to help understand the range of transmission encompassed by the intervention. The patient populations significantly differ; for example, all the infant prophylaxis studies except one (the Breastfeeding, Antiretroviral and Nutrition [BAN] study) enrolled women regardless of CD4 + T-cell count, whereas the three randomized trials of maternal prophylaxis (BAN, Kesho Bora and Mma Bana) restricted enrolment to women with CD4 + T-cell counts ≥200-250 cells/µl (Table 2) . Antepartum antiretroviral drug administration and duration (when given) differs significantly between the studies, yet is clearly important in terms of reducing in utero infection and comparisons of cumulative infection risk. The three large infant prophylaxis studies (the Six Week Extended Nevirapine [SWEN] study, Post-Exposure Prophylaxis of the Infant [PEPI-Malawi] study and BAN) enrolled women who had not received any antepartum drugs, whereas all the maternal prophylaxis studies except one (BAN) provided antepartum drugs (of different durations, ranging from initiation at 25-36 weeks gestation, making comparison even among maternal studies difficult; Table 2 ). The duration of postnatal prophylaxis differs between studies, with two infant prophylaxis studies (SWEN and PEPI-Malawi) providing only 6-14 weeks of postnatal prophylaxis, whereas all of the eight maternal prophylaxis studies provided 6 months of postnatal prophylaxis ( Table 2 ). The duration of breastfeeding, and hence the time at risk for postnatal infection, and rates of exclusive breastfeeding, which can affect postnatal transmission risk, differs between studies and is not specified in several maternal prophylaxis studies (Tables 3 and 4 ). Several studies do not provide birth infection rates, making it difficult to compare the incremental benefit of interventions during the breastfeeding period because the proportion of infections occurring in utero (and hence not affected by a postnatal intervention) cannot be determined (Tables 3  and 4 ). For example, the Mma Bana trial of maternal No comparison group (see Table 3 [21] Table 3 [ Table 3 [28] Table 3 [ Table 3 [30] Cumulative at 6 months: 5.0% Not specified [28] Observational to 6 months CD4≤250); specified (counselled to Cumulative at 6 weeks: prophylaxis (Tables 2 and 4) , which reported the lowest rate of infant infection of all studies to date (cumulative infection 1% at age 6 months) had a median maternal CD4 + T-cell count at enrolment of approximately 400 cells/µl, baseline HIV RNA levels prior to initiation of prophylaxis of 9,100-13,300 copies/ml, median duration of antepartum prophylaxis of 11 weeks, a proportion of infants exclusively breastfeed through age 6 months of 93%, and an adherence rate to maternal prophylaxis of 93% [32] . By contrast, in the maternal prophylaxis arm of the Kesho Bora trial (Tables 2 and  4 ), where the 6-month cumulative HIV infection rate was 4.9%, the median maternal CD4 + T-cell count at enrolment was 335 cell/µl, median duration of antepartum prophylaxis was 6 weeks, and only 48% of infants exclusively breastfed to 3 months [31] . Thus, it is difficult to make direct comparisons even between studies of similar interventions.
Given these caveats, the currently available data suggest that provision of antiretroviral drugs to the breastfeeding infant could have comparable efficacy to provision of maternal combination antiretroviral prophylaxis to the lactating mother. Tables 3 and 4 provide data on six infant prophylaxis studies and eight maternal prophylaxis studies aimed at reducing postnatal transmission that have been published or presented at meetings as of February 2010, and includes data on the timing and type of prophylaxis, numbers enrolled, maternal CD4 + T-cell count and HIV RNA level (when available), infant feeding and duration of feeding, transmission rates at birth, 4-6 weeks and 6-7 months, the incremental risk of early (before 4-6 weeks) and late (between 4-6 weeks and 6-7 months) postnatal infection (when available) and rates of HIV or death (HIVfree survival, when available) [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] .
Because of differences among the studies in administration of maternal antepartum antiretroviral drugs, comparison of cumulative rates of transmission is misleading when trying to compare the effect of the interventions to reduce breast milk transmission. This is because the infection rate at birth, reflecting in utero infection, will be lower if the mother has received drugs during pregnancy than if she received no drugs, and further will be lower with longer than with shorter duration of antepartum drug administration. Therefore, when considering the effect of the postpartum intervention, the better comparison is the rate of infection at 4-6 weeks or 6-7 months in infants who are uninfected at birth; however, many of the maternal prophylaxis studies do not provide information on infection rates at birth, and, as a result, only the comparison of late postnatal infection occurring between 4-6 weeks and 6-7 months was possible between maternal and infant strategies. Another problem is that the duration of the actual postnatal intervention also differs between the studies. Specifically, two large infant prophylaxis randomized trials provided 6 and 14 weeks of prophylaxis, whereas all the maternal studies provided 6 months of prophylaxis; thus, comparisons of late transmission might also be misleading.
In the four maternal prophylaxis and the four infant prophylaxis studies with adequate information for a meaningful comparison of early postnatal infection rates (that is, studies that provided transmission rates at birth to allow assessment of in utero infection and 4-6 week data to allow description of the increment in infection between birth and 4-6 weeks of age), the rate of infection at age 4-6 weeks in infants uninfected at birth with maternal prophylaxis was 0% in Amata and Mma Bana studies, 1.5% in the Kisumu Breastfeeding Study (KiBS), and 1.5% in the Kesho Bora study (Table 4) [28, [30] [31] [32] , and with infant prophylaxis was 0.8% in the Stopping Infection from Mother to Child via Breastfeeding in Africa (SIMBA) study, 1.3% in the Mashi study, 1.7% in the PEPI-Malawi study and 2.5% in the SWEN study (Table 3 ) [20, [22] [23] [24] . Thus, the early (between birth and age 4-6 weeks) postnatal infection rates appear relatively similar with either maternal (range 0-1.5%) or infant (range 0.8-2.5%) interventions.
Although the ability to evaluate late postnatal infection between 4-6 weeks and 6-7 months of age is possible for most of the studies, it is important to note that in some of the infant prophylaxis studies the intervention stops at 6-14 weeks. In the maternal prophylaxis studies, the rates of late postnatal infection are 0.4% (Mma Bana study), 0.5% (Amata study), 0.8% (Drug Resource Enhancement against AIDS and Malnutrition [DREAM] study [27] ), 1.0% (Mitra-Plus study), 1.5% (DREAM study [26] ), 1.6% (Kesho Bora study), and 2.6% (KiBS study; Table 4 ) [25] [26] [27] [28] [29] [30] [31] [32] . In the infant prophylaxis studies, in which infant prophylaxis was given for 6 months as in the maternal studies allowing a comparison of prophylaxis over similar time periods, the rates of late postnatal infection were 0.8% (SIMBA study), 1.2% (Mitra study) and 4.4% (Mashi study; Table 3 ) [20] [21] [22] . Of note, the one infant prophylaxis study with the highest rate of late infection (4.4%) gave infant zidovudine prophylaxis, whereas all the others used nevirapine or lamivudine [20] . The late infection rate in the PEPI-Malawi study, where infant prophylaxis stopped at 14 weeks, was 2.3% [24] . The SWEN study only administered 6 weeks of infant prophylaxis and therefore no prophylaxis was being received during the period of late transmission risk (after age 6 weeks) [23] . Thus, in the evaluable studies, the late (4-6 weeks to 6 months) postnatal infection rates also appear relatively similar with either maternal (range 0.4-2.6%) or infant (range 0.8-4.4%) interventions. In studies that provided data on the end point of HIV or death, comparisons at age 6-7 months ranged from 4.7-8.6% in the maternal prophylaxis studies and 2.9-8.5% in infant prophylaxis studies.
Taken together, the early and late postnatal infection rates appear relatively low and similar with either maternal or infant interventions if being compared during similar periods of prophylaxis. The Mitra study of infant prophylaxis and Mitra-Plus study of maternal prophylaxis provide a non-randomized comparison of interventions, as both studies were conducted sequentially in the same clinics, both provided some maternal antepartum antiretroviral prophylaxis, and both provided the same duration (6 months) of postnatal prophylaxis (Table 2 ) [21, 29] . The cumulative transmission risk at 6 months was 4.9% with infant prophylaxis in Mitra and 5.0% with maternal prophylaxis in Mitra-Plus, and the risk of late transmission between 6 weeks and 6 months was 1.2% with infant prophylaxis and 1.0% with maternal prophylaxis (Tables 3 and 4) .
Data from a randomized comparison of maternal and infant interventions for prevention of postnatal transmission is available from the BAN study, which compared 6 months of maternal prophylaxis or infant nevirapine prophylaxis to a control short-course arm with no maternal or infant prophylaxis during breastfeeding (Table 2 ) [25] ; this study evaluated an intrapartum and postpartum intervention (no maternal antenatal drugs were received) and enrolled women with CD4 + T-cell counts >250 cells/µl. Postnatal transmission rates at age 28 weeks (7 months) in infants uninfected at age 2 weeks were 6.4% in the control arm compared with 3.0% in the maternal prophylaxis arm (P=0.0032 versus control) and 1.8% in the infant nevirapine arm (P<0.0001 versus control; Table 2 ). Although the transmission rate in the infant nevirapine arm appeared lower than in the maternal prophylaxis arm, there was no significant difference between maternal and infant prophylaxis arms (P=0.12) and the study was not powered to detect a difference between the two experimental arms.
The data from these studies also indicate the importance of providing antiretroviral drugs during the antepartum period, and that longer antepartum prophylaxis is more effective than shorter prophylaxis. In the maternal prophylaxis studies where initiation of antiretroviral prophylaxis started at 25-34 weeks gestation, overall 6-7 month transmission rates were 1-5% (Table 4) [26] [27] [28] [29] [30] [31] [32] . In the infant prophylaxis studies in which maternal antepartum prophylaxis was given but started significantly later, at 34-36 weeks gestation, overall 6-7 month transmission rates were 5-9% [20] [21] [22] , whereas in the infant prophylaxis studies where no maternal antepartum drugs were received, overall 6 month transmission rates were approximately 11-12% [23, 24] (Table 3) . Thus, for optimal prevention of mother-to-child transmission, it is crucially important to identify HIV-infected women early in pregnancy and initiate prophylaxis by at least 28 weeks gestation, if not earlier.
Given two presumably similarly effective interventions, the choice of intervention to prevent motherto-child transmission for women who do not require treatment for their own health will involve weighing a number of different considerations, including relative costs, feasibility, and risks and benefits of the interventions (Table 5 ). Few studies have evaluated the cost-effectiveness of these two interventions [34] . When administering maternal triple-drug combination therapy solely for prevention of transmission, the risks of maternal drug toxicities, treatment interruption following prolonged exposure to three drug combination prophylaxis during pregnancy and breastfeeding (presuming treatment stops after cessation of breastfeeding), and of fetal exposure to multiple drugs, need to be weighed against the incremental benefit in preventing transmission compared to less complex regimens in the population of women who do not yet need treatment for their own health. Infant prophylaxis is less expensive but might be programmatically more difficult to implement if combined with use of zidovudine plus single-dose nevirapine plus a 'tail' to reduce nevirapine resistance and prevent in utero/intrapartum infection. None of the studies to date have been adequately powered to address the comparative efficacy and safety of maternal versus infant prophylaxis, and although there are studies planned (Table 6 ), data will not be available for several years. Table 7 summarizes toxicity reports from the infant and maternal prophylaxis studies. Evaluation of safety can be best assessed in the randomized clinical trials. The SWEN and PEPI-Malawi large randomized clinical trials of 6 and 14 weeks of extended daily infant nevirapine prophylaxis (Table 2) , respectively, together enrolled 5,090 infants [23, 24] . There were no significant differences in infant adverse events (including rash and hepatic events) between the experimental and control arms (control arm was single-dose nevirapine in SWEN and single-dose nevirapine plus 1 week of infant zidovudine in PEPI-Malawi). The SWEN trial found significantly lower infant mortality at 6 months in the extended nevirapine group compared with the control arm, whereas the PEPI-Malawi trial found similar rates of mortality at 9 months between the two extended infant prophylaxis arms and the control arm (Table 7) .
Safety of infant and maternal antiretroviral prophylaxis
In the PEPI-Malawi trial, infants in the extended dual nevirapine/zidovudine prophylaxis arm had a significantly higher number of infant adverse events deemed possibly related to study drug (primarily neutropaenia) compared with the control group (Table 7 ) [24] . Thus, the addition of zidovudine potentially increased toxicity of the extended infant prophylaxis, without increasing efficacy, as there was no significant difference in efficacy between the two extended prophylaxis arms [24] . The Mashi trial randomized infants to formula feeding with 1 month of infant zidovudine or to infant breastfeeding with 6 months of infant zidovudine. There were significantly higher rates of grade 3 or 4 signs or symptoms in infants receiving 6 months versus 1 month of zidovudine and higher rates of grade 3 or 4 laboratory abnormalities, particularly neutropaenia, similar to the PEPI-Malawi trial (Table 7 ) [20] . Finally, the SIMBA trial compared extended infant prophylaxis with daily lamivudine or daily nevirapine; there were no significant differences in serious adverse events or mortality between the two study arms [22] .
The BAN trial compared 6 months of maternal tripledrug combination prophylaxis and 6 months of infant daily nevirapine prophylaxis to a control intervention of single-dose nevirapine with 1 week of zidovudine/ lamivudine (Table 2) . Mothers in the triple-drug combination prophylaxis arm had significantly higher rates of grade 3 or 4 neutropaenia than those in the infant No indication of adverse effect on pregnancy outcome. Potential increase in preterm delivery or low birth weight outcome safety with maternal triple-drug regimen seen in some studies in resource-limited and resource-rich countries.
Maternal safety
Use of intrapartum sdNVP can be associated with NVP Possible higher rates of haematological toxicity. resistance in mother, hence need for AZT/3TC (or other Effect on maternal health of interruption of drugs drug) 'tail' to prevent resistance. No maternal drugs postpartum.
after prolonged use during pregnancy and breastfeeding and of repeated courses with subsequent pregnancies is a concern. No data on prophylaxis extended past 6 months. Infant safety Up to 6 months of daily NVP prophylaxis is safe. No data Infant exposed to subtherapeutic levels of antiretroviral on more prolonged prophylaxis yet. drugs in maternal milk, although BAN trials suggests similar safety between infant and maternal prophylaxis.
Resistance
If infant is receiving prophylaxis during breastfeeding and If mother is receiving triple-drug during breastfeeding and becomes infected, drug resistance likely.
infant becomes infected, drug resistance is likely.
Choice of drug
Extended prophylaxis with infant NVP as effective as More complicated: NVP hepatotoxicity a concern; in NVP/AZT (PEPI-Malawi study) resource-rich countries, protease-inhibitor-based regimens used for prophylaxis; use of EFV for prolonged periods postpartum a concern regarding risk for teratogenicity should woman become pregnant again.
Complexity
Use of AZT/sdNVP and 'tail' is more complex. Use of single regimen during pregnancy and postpartum might be easier to implement. Assessment of CD4 prior to initiation important to determine which CD4 prior to initiation important as maternal drugs are mother for women require treatment for own health. CD4 could be stopped after infection risk ceases (should not stop treatment need obtained and antepartum AZT (or postnatal NVP) initiated drugs if maternal CD4<350). Regimen likely to be (for example, while waiting for result; women with CD4<350 can then different for women with CD4>350 where NVP cannot be CD4 count) be switched to cART for own health which also provides safely used. postnatal prophylaxis. Haemoglobin: at delivery, 2.7%, 1.8%; at 3 months 0.8%, 0.5%;
Haemoglobin: at delivery, 14.6%, 12.0%; at 3 months 0.6%, 0.6%; Neutrophils: at delivery, 0.3%, 0%; at 3 months, 2.1%, 0.8%; Neutrophils: at delivery, 7.8%, 8.4%; at 3 months, 0.6%, 0.9%; ALT: at delivery, 0.8%,0%; at 3 months 0%, 0%; ALT: at delivery, 0.3%, 0.3%; at 3 months 0%, 0%; Mortality (12 months): 1.2%, 1.2% Mortality (12 months): 6.7%, 10.2%
prophylaxis or control arms (Table 7 ) [25] . Infant haematological and liver adverse events were similar in all three study arms but rash events were significant greater in the infant prophylaxis arm, although the proportion with rash only was 1.8%; all rash events resolved with change from daily nevirapine to daily lamivudine infant prophylaxis.
The Kesho Bora randomized trial compared antepartum and extended postpartum maternal triple-drug combination therapy to a control arm of zidovudine/single-dose nevirapine without extended postpartum prophylaxis (Table 2 ). There were no significant differences in serious adverse events in mothers or infants between study arms or in maternal or infant mortality (Table 7 ) [31] .
The Mma Bana study compared two different maternal combination antiretroviral prophylaxis interventions (zidovudine/lamivudine/abacavir versus zidovudine/ lamivudine/lopinavir/ritonavir; Table 2 ). There was no significant difference in the number of women or infants with grade 3 or 4 diagnoses, grade 3 or 4 laboratory events, or maternal and infant mortality at 6 months between the arms (Table 7 ) [32] . The rate of preterm delivery, however, was significantly higher in the lopinavir/ritonavir arm than the triple nucleoside arm, 23% versus 15%, respectively (P=0.04). The rate of low birth weight infants was also higher, 17% versus 13%, although this difference was not statistically significant. There have been some other reports of increased rates of preterm delivery or low birth weight with use of combination triple-drug prophylaxis in other resource-limited countries (Côte d'Ivoire and South Africa) [35, 36] . In resource-rich countries, there are conflicting reports regarding pregnancy outcome and use of triple-drug prophylaxis [37, 38] .
The combined data suggest that daily infant nevirapine prophylaxis, studied in 3,016 infants in the SWEN, PEPI-Malawi, SIMBA and BAN trials, appears safe for the infant compared with control interventions, with the exception of a higher number of rashes seen in the BAN study only (although the incidence of grade 3 or 4 rash in BAN was <2%). Use of zidovudine for infant prophylaxis, either alone or in combination with nevirapine, is associated with higher rates of haematological toxicity in infants. Similarly, maternal prophylaxis, studied in 1,824 mother-infant pairs in the Kesho Bora, BAN and Mma Bana trials, appears safe for both the mother and the infant compared with control interventions, although the rate of maternal neutropaenia might be increased (BAN trial). There was, however, a concerning increase in the rate of preterm delivery in infants born to mothers receiving extended maternal prophylaxis with a lopinavir/ritonavir-based combination drug regimen in the Mma Bana trial, and enhanced surveillance for adverse pregnancy outcome as use of maternal tripledrug prophylaxis increases is warranted.
Drug resistance with infant or maternal antiretroviral prophylaxis of postnatal transmission
There are concerns regarding potential drug resistance in infants infected postnatally, despite either infant or maternal antiretroviral prophylaxis interventions, and further studies are needed to better define risk.
High rates of nevirapine resistance were seen in breastfed infants in the SWEN study of 6 weeks of infant nevirapine prophylaxis: 92% of infants who became infected during the first 6 weeks of life (that is, during the period of extended prophylaxis) had nevirapine resistance compared with 38% exposed to single-dose nevirapine only [39] . Although the addition of zidovudine to the infant nevirapine prophylaxis regimen in the PEPI-Malawi study did result in lower nevirapine resistance among infants infected despite prophylaxis (62% had resistance mutations with extended nevirapine plus zidovudine compared to 86% with extended nevirapine prophylaxis; P=0.015), this was only if prophylaxis was discontinued before age 6 weeks, and resistance was still observed in a significant proportion of infected infants [40] .
Antiretroviral drug resistance has also been observed in infants infected despite prophylaxis with maternal triple-drug combinations. Three studies have now identified multiclass drug resistance (mutations conferring resistance to nucleoside analogue reverse transcriptase inhibitor drugs as well as to the non-nucleoside drug class) in breastfeeding infants who have become infected despite maternal triple-drug prophylaxis [41] [42] [43] It is known that some antiretroviral drugs enter breast milk, and that the concentration of drug in milk varies by drug. The drug lamivudine appears to concentrate in breast milk, and is present at levels 3-5× that in maternal plasma, whereas zidovudine appears to be present at levels similar to or somewhat less than maternal plasma [44] . Nevirapine levels are only approximately 60-75% of maternal plasma, and the protease inhibitors that have been studied have reported very limited data on breast milk [45] . Thus, breastfeeding infants who become infected could be ingesting subtherapeutic levels of antiretroviral drugs present in the breast milk of mothers receiving combination drug prophylaxis, and could therefore develop drug-resistant virus.
Although the development of resistance in infants infected despite infant or maternal antiretroviral prophylaxis is concerning, it should be noted that the proven efficacy of antiretroviral prophylaxis of the infant or mother to prevent postnatal MTCT means that such regimens remain an attractive choice overall. That is, although a larger proportion of children who become infected while receiving prophylaxis will develop resistance, the absolute number of children who develop resistance is small because the breastfeeding prophylaxis prevents a substantial number of infections.
Duration of prophylaxis
Both maternal and infant antiretroviral interventions evaluated to date are predicated upon early weaning of the infant, generally at or prior to age 6 months. However, increasing data, including that from the infant and maternal prophylaxis trials, suggest that shortening the duration of breastfeeding to 6 months could be associated with increased risk of malnutrition and infant mortality caused by infectious diseases. Although some of the studies are problematic (for example, by using historical controls or not accounting for seasonality of diarrhoeal illness), the cumulative data suggest that shortening breastfeeding duration is problematic in many settings. In the postnatal prophylaxis trials, it is clear that HIV transmission risk resumes once prophylaxis is stopped if breastfeeding continues [20, 23, 24] ; therefore, evaluation of the safety, additional efficacy and cost-effectiveness of more extended postnatal prophylaxis to allow for more prolonged breastfeeding is warranted. Several planned clinical trials are evaluating longer durations of infant prophylaxis, ranging from 9 to 18 months (ANRS-PEP, PROMISE and ANRS 12200; Table 6 ).
In the Zambia Exclusive Breastfeeding trial, early abrupt cessation of breastfeeding at 4 months by HIVinfected mothers in Zambia did not improve the rate of HIV-free survival among children born to HIV-infected mothers and was harmful to HIV-infected infants [46] . In the PEPI-Malawi infant prophylaxis study, where weaning at 6 months of age was recommended, there was a significantly higher incidence of gastroenteritis and infant mortality in the period immediately following breastfeeding cessation when compared to an historical control with continued breastfeeding [47] . In a study of 118 infants born to women receiving triple-drug antiretroviral therapy during pregnancy and breastfeeding in rural Uganda, the median duration of breastfeeding was 5 months. In multivariate analysis, there was a sixfold greater risk of death among infants breastfed for <6 months independent of maternal CD4 + T-cell count closest to delivery, maternal marital status or maternal death (adjusted hazard ratio =6.19; 95% confidence interval 1.41-27.00; P=0.015) [48] . Similarly, in the KiBS open-label study of maternal tripledrug prophylaxis, an increase in serious gastroenteritis events, hospitalizations and growth faltering were observed following early breastfeeding cessation around 6 months of age [49] . Additionally, in the Mashi study, discontinuation of breastfeeding was the primary risk factor for serious infant morbidity [20] . Finally, in an outbreak of diarrhoeal disease associated with heavy rains in Botswana in 2006, a cross-sectional survey found that one-third of children <5 years of age had diarrhoea, which increased levels of acute malnutrition and mortality among children [50] . Breastfeeding was found to be protective, whereas age under 2 years and being HIV-exposed was a risk factor for diarrhoea; this was particularly relevant because national policy in Botswana at that time was for HIV-infected mothers to formula-feed their infants.
WHO has recently revised their guidelines for infant feeding by HIV-infected women, based in part on the clinical trials demonstrating the effectiveness of infant and maternal antiretroviral prophylaxis to reduce postnatal HIV transmission [51] . It is now recommended that national or subnational guidelines be developed to support either breastfeeding accompanied by postnatal infant nevirapine or maternal triple-drug antiretroviral prophylaxis for women with CD4 + T-cell count >350 cells/µl or antiretroviral treatment for women with CD4 + T-cell count <350 cells/µl, or avoidance of all breastfeeding, based on economic and cultural factors, available health services, local epidemiology and infant mortality rates [51] . If breastfeeding is recommended on the national level, exclusive breastfeeding through age 6 months, followed by continued breastfeeding with addition of complementary foods through age 12 months is recommended; gradual weaning over 1 month is recommended, with discontinuation of antiretroviral prophylaxis 1 week after complete cessation of breastfeeding.
Conclusions
Prevention of mother-to-child HIV transmission during breastfeeding remains a challenge but we now have new antiretroviral-based prophylaxis approaches that can allow safer and more prolonged breastfeeding by HIVinfected women. There is a crucial need to initiate antiretroviral therapy among pregnant and lactating HIVinfected women who meet existing criteria for treatment; this intervention would have substantial effect on both maternal mortality and HIV transmission to the infant. In women who do not require treatment, both infant antiretroviral prophylaxis and maternal combination tripledrug prophylaxis appear to have similar efficacy and both approaches appear relatively safe; however, each has pros and cons that countries will need to consider when choosing which to implement on a population basis. Longer duration of prophylaxis than has been studied to date (6 months) appears advisable in terms of infant survival. Pharmacovigilance to evaluate the safety of longer term use of these interventions as well as to evaluate the effect of maternal prophylaxis on pregnancy outcome will be crucial as these interventions are implemented.
